Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459711 | 1.00 | KIF11 (0.65) | KIF11DNMT1 | |
| SCHEMBL29635035 | 1.00 | KIF11 (0.65) | KIF11DNMT1 | |
| Hydrochloric Acid SCHEMBL25242234 | 0.99 | KIF11 (0.64) | KIF11DNMT1 | |
| Hydrochloric Acid SCHEMBL4459708 | 0.99 | KIF11 (0.64) | KIF11DNMT1 | |
| Hydrochloric Acid SCHEMBL4459715 | 0.99 | KIF11 (0.64) | KIF11DNMT1 | |
| SCHEMBL30745107 | 0.90 | KIF11 (0.64) | KIF11DNMT1 | |
| SCHEMBL8036028 | 0.89 | KIF11 (0.60) | KIF11DNMT1 | |
| SCHEMBL12872399 | 0.85 | KIF11 (0.85) | KIF11DNMT1 | |
| SCHEMBL3439368 | 0.85 | KIF11 (0.85) | KIF11DNMT1 | |
| SCHEMBL9137501 | 0.85 | KIF11 (0.85) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097207-A1 | SYNTHETIC PROCESS FOR PRODUCTION OF MODIFIED GCC RECEPTOR AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GIMI RAYOMAND H | 2006-12-14 | — | — | US | disclosed |
| US-7115769-B2 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1529037-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Genzyme Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| WO-2003097622-A2 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | KIF11 4699/4885DNMT1 1291/4885 |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | KIF11 4699/4885DNMT1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.